Health
Pancreatitis drug blocks SARS-CoV-2 activators in the upper respiratory tract – News-Medical.Net
Pancreatitis drug Camostat inhibits new SARS-CoV-2 activators identified in the upper respiratory tract.
There are no therapeutics available that have been developed…
Pancreatitis drug Camostat inhibits new SARS-CoV-2 activators identified in the upper respiratory tract.
There are no therapeutics available that have been developed for COVID-19 treatment. Repurposing already available medication for COVID-19 therapy is an attractive option to shorten the road to treatment development.
The drug Camostat could be suitable. Camostat exerts antiviral activity by blocking the protease TMPRSS2, which is used by SARS-CoV-2 for entry into cells.
However, it was previously…
-
Noosa News8 hours agoHow Lily Steele-Park took her rapist to court and won
-
General22 hours ago‘Potential’ hacker contacts Qantas over data breach
-
Business12 hours agoFord CEO makes stunning prediction about artificial intelligence
-
General24 hours agoFears for next anti-Semitic firebombing on home soil